IBD / Crohn's Disease & Medical Cannabis

IBD as a Qualifying Condition

Inflammatory bowel disease (IBD) — including Crohn's disease and ulcerative colitis — is a qualifying condition for the NJ Medical Marijuana Program. IBD is a chronic inflammatory condition of the gastrointestinal tract that can cause debilitating abdominal pain, diarrhea, bloody stools, fatigue, and significant impact on quality of life.

Many patients with IBD try multiple medications — including immunosuppressants and biologics — with incomplete response or significant side effects. For these patients, medical cannabis represents an additional therapeutic option with a growing evidence base.

How Cannabis May Help

The gut is richly supplied with endocannabinoid receptors. Cannabis — particularly CBD-dominant preparations — has demonstrated anti-inflammatory effects in gastrointestinal tissue, reduced intestinal motility in some contexts, and pain-reducing and anti-nausea effects that can significantly improve symptom control in IBD patients.

Clinical studies in Crohn's disease patients have reported reductions in disease activity scores, improved quality of life, and reduced need for corticosteroids in patients using medical cannabis. Evidence is considered promising though studies are still ongoing.

Managing IBD With Cannabis

Your provider will consider your specific disease type (Crohn's vs. UC), disease activity, current medications, and overall health when making recommendations. Cannabis is typically used as an adjunct to — not a replacement for — your existing IBD management regimen. We coordinate with your gastroenterologist when needed.